Donate to PCRI: https://pcri.org/donate/
For more information, visit https://pcri.org
1:34 What is a biomarker test?
3:55 How can patients be sure that it's safe to forego hormone therapy?
7:21 Why do one-third of patients benefit from ADT?
10:04 What markers point toward hormone therapy being necessary?
11:20 What PSA and PSMA results indicate that a patient should try hormone therapy?
12:09 Is age often a factor when deciding to embark on hormone therapy?
13:20 How would a biomarker test help a patient decide on whether to start hormone therapy?
14:26 What were the results of the Phase 3 randomized studies on ArturaAI?
15:33 How should patients decide between IMRT and brachytherapy?
17:23 How does IMRT alone compare to IMRT with hormone therapy?
18:18 How advisable is it for the average patient to get the ArturaAI test?
19:48 Does taking hormone therapy later lessen its effectiveness?
21:29 Alex's conclusions
Don't know your stage? Take the quiz: visit http://www.prostatecancerstaging.org
To learn more about prostate cancer, visit http://www.pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: https://pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.